Baird raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $72 and keeps a Neutral rating on the shares. The firm updated its model following somewhat mixed Q1 results as they reiterated 2025 growth guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences upgraded to Overweight from Neutral at Piper Sandler
- Edwards Lifesciences Reports Strong Q1 Growth
- Edwards Lifesciences: Hold Rating Amid Strong Q1 Results and Future Challenges
- Closing Bell Movers: Robert Half down 15% after earnings miss
- Edwards Lifesciences reaffirms FY25 adjusted EPS $2.40-$2.50, consensus $2.45